US Patent

US8669273 — Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Method of Use · Assigned to Wyeth LLC · Expires 2031-07-18 · 5y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a combination of a 4-anilino-3-cyanoquinoline compound and a capecitabine compound for treating various types of cancer.

USPTO Abstract

A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3047 — neratinib-maleate

Patent Metadata

Patent number
US8669273
Jurisdiction
US
Classification
Method of Use
Expires
2031-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.